Tonix Pharmaceuticals Holding Corp (TNXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $58.49M
Last updated: Nov 17, 2026 at 11:06 AM ET
Tonix Pharmaceuticals Holding Corp (TNXP) Earnings: Report Dates and Results
Tonix Pharmaceuticals Holding (TNXP) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Tonix Pharmaceuticals Holding reported EPS of -$2.89, below the -$2.51 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TNXP has an expected report date of Mar 10, 2027.
TNXP Earnings Call
The latest TNXP earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, TNXP beat 15, missed 15 and matched 10. Revenue for the quarter ended Sep 30, 2026 was $17.23M, up 423.7% from $3.29M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$2.89 | -$2.51 | N/A | -15.14% | Miss | N/A | 3 | 1 up, 0 down | Nov 9, 2026 | $17.23M |
| Jun 30, 2026 | -$2.44 | -$2.71 | -$2.76 - -$2.48 | +9.96% | Beat | N/A | 2 | 0 up, 1 down | Aug 10, 2026 | $13.54M |
| Mar 31, 2026 | -$2.93 | -$2.54 | -$2.98 - -$2.10 | -15.35% | Miss | N/A | 2 | 0 up, 1 down | May 11, 2026 | $6.88M |
| Dec 31, 2025 | -$3.98 | -$3.19 | N/A | -24.82% | Miss | N/A | 1 | 1 up, 0 down | Mar 12, 2026 | $5.39M |
| Sep 30, 2025 | -$3.70 | -$2.75 | -$2.75 - -$2.75 | -34.55% | Miss | N/A | 1 | 1 up, 0 down | Nov 10, 2025 | $3.29M |
| Jun 30, 2025 | -$4.00 | -$1.88 | -$1.88 - -$1.88 | -112.77% | Miss | N/A | 1 | 1 up, 0 down | Aug 11, 2025 | $2.00M |
| Mar 31, 2025 | -$2.64 | -$3.09 | -$3.09 - -$3.09 | +14.56% | Beat | N/A | 1 | 1 up, 0 down | May 12, 2025 | $2.43M |
| Dec 31, 2024 | -$9.77 | -$3.91 | N/A | -149.80% | Miss | N/A | N/A | 0 up, 0 down | Mar 18, 2025 | $2.58M |
| Sep 30, 2024 | -$25.56 | -$736.00 | -$736.00 - -$40.00 | +96.53% | Beat | N/A | 3 | 0 up, 0 down | Nov 12, 2024 | $2.82M |
| Jun 30, 2024 | -$464.22 | -$720.00 | -$736.00 - -$118.00 | +35.52% | Beat | N/A | 3 | 1 up, 0 down | Aug 16, 2024 | $2.21M |
| Mar 31, 2024 | -$576.00 | -$1,136.00 | -$1,506.41 - -$993.59 | +49.30% | Beat | N/A | 2 | 0 up, 0 down | Apr 1, 2024 | $2.48M |
| Dec 31, 2023 | -$0.86 | -$1.64 | -$1.83 - -$1.46 | +47.56% | Beat | N/A | 3 | 0 up, 0 down | Mar 25, 2024 | $3.78M |
| Sep 30, 2023 | -$5,856.00 | -$4,496.00 | -$5,320.51 - -$3,750.00 | -30.25% | Miss | N/A | 3 | 1 up, 0 down | Nov 9, 2023 | $3.99M |
| Jun 30, 2023 | -$8,576.00 | -$5,264.00 | N/A | -62.92% | Miss | N/A | 2 | 1 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$10,400.00 | -$11,400.00 | -$11,418.27 - -$8,012.82 | +8.77% | Beat | N/A | 2 | 0 up, 0 down | May 8, 2023 | N/A |
| Dec 31, 2022 | -$0.56 | -$0.86 | -$1.41 - -$0.54 | +34.88% | Beat | N/A | 3 | 0 up, 0 down | Mar 13, 2023 | N/A |
| Sep 30, 2022 | -$13,800.00 | -$26,400.00 | -$26,442.31 - -$14,423.08 | +47.73% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2022 | N/A |
| Jun 30, 2022 | -$24,400.00 | -$28,600.00 | N/A | +14.69% | Beat | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | N/A |
| Mar 31, 2022 | -$32,000.00 | -$32,000.00 | -$32,102.65 - -$25,682.12 | 0.00% | In line | N/A | 3 | 0 up, 0 down | May 9, 2022 | N/A |
| Dec 31, 2021 | -$2.24 | -$1.92 | -$2.24 - -$1.60 | -16.67% | Miss | N/A | 2 | 0 up, 0 down | Mar 14, 2022 | N/A |
| Sep 30, 2021 | -$32,000.00 | -$44,800.00 | N/A | +28.57% | Beat | N/A | 2 | N/A | Nov 8, 2021 | N/A |
| Jun 30, 2021 | -$44,800.00 | -$38,400.00 | N/A | -16.67% | Miss | N/A | 2 | N/A | Aug 9, 2021 | N/A |
| Mar 31, 2021 | -$44,800.00 | -$38,400.00 | -$38,523.18 - -$32,102.65 | -16.67% | Miss | N/A | 2 | N/A | May 10, 2021 | N/A |
| Dec 31, 2020 | -$3.20 | -$2.40 | -$2.56 - -$2.24 | -33.33% | Miss | N/A | 2 | N/A | Mar 15, 2021 | $2.91M |
| Sep 30, 2020 | -$57,600.00 | -$70,400.00 | N/A | +18.18% | Beat | N/A | 2 | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$147,200.00 | -$134,400.00 | N/A | -9.52% | Miss | N/A | 2 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$9.60 | -$10.08 | -$13.46 - -$6.73 | +4.76% | Beat | N/A | 2 | N/A | May 12, 2020 | N/A |
| Dec 31, 2019 | -$1,000,000.00 | -$953,600.00 | -$1,123,592.62 - -$789,725.10 | -4.87% | Miss | N/A | 2 | N/A | Mar 24, 2020 | N/A |
| Sep 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 2 | N/A | Nov 8, 2019 | N/A |
| Jun 30, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 3 | N/A | Aug 12, 2019 | N/A |
| Mar 31, 2019 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 2 | N/A | May 13, 2019 | N/A |
| Dec 31, 2018 | -$1,952.00 | -$1,172.27 | -$1,250.00 - -$1,041.67 | -66.51% | Miss | N/A | 3 | N/A | Mar 18, 2019 | N/A |
| Sep 30, 2018 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 9, 2018 | N/A |
| Jun 30, 2018 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 4 | N/A | Aug 13, 2018 | N/A |
| Mar 31, 2018 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | 1 | N/A | May 14, 2018 | N/A |
| Dec 31, 2017 | -$2,176.00 | -$2,480.00 | -$2,564.10 - -$2,403.85 | +12.26% | Beat | N/A | 2 | N/A | Mar 12, 2018 | N/A |
| Sep 30, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 7, 2017 | N/A |
| Jun 30, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 14, 2017 | N/A |
| Mar 31, 2017 | -$1,000,000.00 | -$1,000,000.00 | N/A | 0.00% | In line | N/A | N/A | N/A | Apr 17, 2017 | N/A |
| Dec 31, 2016 | -$2.97 | -$130.00 | N/A | +97.72% | Beat | N/A | N/A | N/A | Mar 3, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$14.32, after -$1,075.55 the year before. It was -$3,000,002.97 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$14.32 | N/A |
| Dec 31, 2024 | -$1,075.55 | N/A |
| Dec 31, 2023 | -$24,832.86 | N/A |
| Dec 31, 2022 | -$70,200.56 | N/A |
| Dec 31, 2021 | -$121,602.24 | N/A |
| Dec 31, 2020 | -$204,812.80 | N/A |
| Dec 31, 2019 | -$4,000,000.00 | N/A |
| Dec 31, 2018 | -$3,001,952.00 | N/A |
| Dec 31, 2017 | -$3,002,176.00 | N/A |
| Dec 31, 2016 | -$3,000,002.97 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,975 | 10 | |
| 2026Q2 | Jun 30, 2026 | 4,971 | 8 |
2026Q3 Earnings Call
Opening remarks
Deborah Elson Head of Investor Relations Thank you, operator, and good morning, everyone. Thank you for joining us to discuss Tonix Pharmaceuticals' Third Quarter 2026 Financial Results and Operational Highlights. Before we begin, I would like to refer you to the forward-looking statements disclaimers on Slide 2. Any statements made on today's call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA and any of our approved products, uncertainties of patent protection and litigation, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations, risks related to the timing and progress of clinical development of our product candidates, our need for additional financing, uncertainties of government or third-party payer reimbursement, limited research and development efforts and dependence upon third parties, and substantial competition. These risks are described more fully in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2025, and our subsequent quarterly reports on Form 10-Q. Tonix undertakes no obligation to update or revise any forward-looking statements, except as required by law. Joining me on today's call are Dr. Seth Lederman, Chief Executive Officer; Thomas Englese, Chief Commercial Officer; and Bradley Saenger, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. With that, I will turn the call over to Seth. Seth?
Seth Lederman Chief Executive Officer Thank you, Deborah, and good morning, everyone. Today, we are reporting our third quarter financial results and operational highlights. Slide 3 outlines our progress in advancing TONMYA's commercial business and priority clinical programs. TONMYA third quarter net sales totaled approximately $15 million, increasing 37% quarter-over-quarter. Previously signed payer agreements contributed to third quarter sales. We have also begun to see promising performance growth since our expanded sales force entered the field on September 1. These positive trends are continuing into the fourth quarter. We remain encouraged by TONMYA's trajectory. With our larger sales force and growing sales, we believe we're well positioned to create value by improving the treatment of fibromyalgia and reinvigorating this market. On October 1, 2026, we received notice from Dr. Reddy's Laboratories that it had filed an abbreviated new drug application, or ANDA, Paragraph IV patent certification for TONMYA. Generic challenges are common in the life cycle of an approved drug. We will vigorously defend and enforce our TONMYA intellectual property rights against infringement. As we prioritize TONMYA's growth, we are also advancing key research and development programs.
Frequently Asked Questions About TNXP
When is Tonix Pharmaceuticals Holding's next earnings date?
Tonix Pharmaceuticals Holding's next earnings report is expected for Mar 10, 2027.
Did TNXP beat earnings estimates last quarter?
No. Tonix Pharmaceuticals Holding reported EPS of -$2.89 for the quarter ended Sep 30, 2026, below the -$2.51 estimate by 15.14%.
What EPS do analysts expect from TNXP next quarter?
The consensus EPS estimate for Tonix Pharmaceuticals Holding for the quarter ending Dec 31, 2026 is -$2.41 from 8 analysts, with estimates from -$2.45 to -$2.39.
How often does TNXP beat earnings estimates?
Tonix Pharmaceuticals Holding beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -40.99%.
TNXP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors